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ABSTRACT
The European Bioinformatics Institute (EMBL-EBI)
provides public access to patent data, including
abstracts, chemical compounds and sequences.
Sequences can appear multiple times due to the
filing of the same invention with multiple patent
offices, or the use of the same sequence by different
inventors in different contexts. Information relating
to the source invention may be incomplete, and bio-
logical information available in patent documents
elsewhere may not be reflected in the annotation
of the sequence. Search and analysis of these data
have become increasingly challenging for both the
scientific and intellectual-property communities.
Here, we report a collection of non-redundant
patent sequence databases, which cover the
EMBL-Bank nucleotides patent class and the
patent protein databases and contain value-added
annotations from patent documents. The databases
were created at two levels by the use of sequence
MD5 checksums. Sequences within a level-1 cluster
are 100% identical over their whole length. Level-2
clusters were defined by sub-grouping level-1
clusters based on patent family information. Value-
added annotations, such as publication number
corrections, earliest publication dates and feature
collations, significantly enhance the quality of the
data, allowing for better tracking and cross-
referencing. The databases are available format:
http://www.ebi.ac.uk/patentdata/nr/.
INTRODUCTION
Patents in the biotechnology domain cover a wide range
of areas, including health (e.g. vaccines, antibodies
and diagnostics), industrial microbiology (e.g. genetically
modiﬁed microbes) and agriculture (e.g. GMO and
cultivars). Thus, the patent data are a valuable resource,
not only for the intellectual-property world but also for
the scientiﬁc community. Information in patent data can
be more detailed (1), appears earlier or is not available in
the scientiﬁc literature (2). The European Bioinformatics
Institute (EMBL-EBI) provides public access to patent
data resources, including abstracts, chemical compounds
and sequences (http://www.ebi.ac.uk/patentdata/). Patent
abstracts contains abstracts of biology-related patent
applications derived from data products of the European
Patent Oﬃce (EPO). Chemical compounds appearing
in patents are available in ChEBI (3), a dictionary of
molecular entities focused on small chemical compounds.
The sequences appearing in patent applications are an
important resource for patent-related searches. During the
past decade, the number of biological sequences appearing
in patent applications has been increasing dramatically
(Figure 1). Today, millions of nucleotide and protein
sequences extracted from the patent documents are
available from both the commercial sector and the
public domain. Proprietary eﬀorts include GENESEQ
TM
(Thomson Reuters) http://thomsonreuters.com/products_
services/science/science_products/life_sciences/biology/
geneseq), GQ-PAT (GenomeQuest, Inc.; http://www
.genomequest.com), CAS REGISTRY (Chemical
Abstracts Service; http://www.cas.org), PCTGEN (FIZ
Karlsruhe; http://www.ﬁz-karlsruhe.de/sci_tech_paten-
t_information.html) and USGENE (SequenceBase
Corporation; http://www.sequencebase.com/) (4) and the
major public databases represented by the International
Nucleotide Sequence Database Collaboration (INSDC;
http://www.insdc.org/) member databases: EMBL-Bank
(5), GenBank (6) and DDBJ (7). These include data
provided by the EPO, Japan Patent Oﬃce (JPO),
Korean Intellectual Property Oﬃce (KIPO) and United
States Patent and Trademark Oﬃce (USPTO). EMBL-
Bank has a speciﬁc data class (PAT) for nucleotide
sequences obtained from patents. The EMBL-EBI also
collates protein sequences provided by the EPO, JPO,
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able from the EMBL-EBI ftp server (ftp://ftp.ebi.ac.uk/
pub/databases/embl/patent/) and via the SRS server
(http://srs.ebi.ac.uk/). FASTA format ﬁles for sequence
searching are also available format: ftp://ftp.ebi.ac.uk/
pub/databases/fastaﬁles/patent/.
Searching patent sequence databases can be used as
inspiration for scientiﬁc innovation and discovery of
existing inventions (e.g. industrial processes) with rele-
vance to the work of the researcher. However, as men-
tioned earlier, sequences may appear multiple times due
to the same invention being ﬁled with multiple patent
oﬃces. Furthermore, the same sequence may be used by
diﬀerent inventors in diﬀerent inventions. Information
relating to the source patent may be incomplete, and bio-
logical information available in the patent document may
not be reﬂected in annotation. Thus, search and analysis
of these data have become increasingly challenging (8,9).
Recent eﬀorts have been made to create non-redundant
patent sequence resources to improve access and direct
analysis of the sequences. PatGen (10), a database con-
taining non-redundant data from the public resources,
allowed queries against patent bibliographic data and
sequences. Unfortunately, the method of redundancy
removal in PatGen has not been detailed to the public
and the database is no longer available online. Patome
(11) is a non-redundant patent sequence set also derived
from the public resources, providing additional
annotations with RefSeq (12), OMIM (13) and Gene
ontology (GO) (14). Patome is useful for the identiﬁcation
of disease-related patent sequences. Duplicated sequences
were removed in Patome according to the patent number
(PN) and the sequence identiﬁer in the sequence listing;
however, identical sequences granted with diﬀerent PNs
by diﬀerent patent oﬃces are not classiﬁed in Patome.
None of these studies attempts to establish publicly
available non-redundant patent sequence databases
based on the sequence level and the patent family level.
In this article, we describe a publicly available collection
of non-redundant patent sequence databases, which have
been created at two levels and cover the EMBL-Bank
patent class nucleotides and the patent proteins from the
EPO, JPO, KIPO and USPTO. The proprietary patent
resources have been excluded due to the restrictions on
their use. The non-redundant sequences are identiﬁed
using MD5 (Message-Digest algorithm 5) (http://www.
faqs.org/rfcs/rfc1321.html) checksums of the sequences.
Members of a level-1 cluster are 100% identical over
their whole length. Level-2 clusters are deﬁned by sub-
grouping level-1 clusters based on the patent equivalents
which have been published by diﬀerent patent oﬃces
for a single invention. The clusters contain value-added
annotations, such as publication patent corrections
and earliest publication dates. Level-2 clusters also
oﬀer merged biological features. The data collection
signiﬁcantly enhances the quality of patent sequence
data and allows for better tracking and cross-referencing
in patent search.
DATA COLLECTION AND DATABASE CONTENTS
Redundancy removal
The source data used in this study were obtained from the
EMBL-Bank PAT data class (see: http://www.ebi.ac
.uk/patentdata/nucleotides/), these include the patent
sequences submitted through the INSDC member
databases; and the protein sequence data provided by
EPO, JPO, KIPO and USPTO (see: http://www.ebi.ac
.uk/patentdata/proteins/). The consistent use of data
formats, especially the feature tables, simpliﬁes down-
stream data processing.
Data redundancy was removed in two steps and two
non-redundant databases were generated at diﬀerent
levels. The level-1 was deﬁned by identifying sequences
at 100% identity over the whole sequence length and
grouped into clusters (Figure 2). A number of methods
for identifying identical sequences were evaluated
(Supplementary Data Section 2):
(i) Cyclic Redundancy Check (CRC) checksum
(http://en.wikipedia.org/wiki/Cyclic_redundancy_
check): the CRC32 (IEEE 802.3) and CRC64-ISO
(ISO 3309) checksums commonly used in the
sequence databases were found to be insuﬃciently
robust to uniquely identify the sequences. The
alternative CRC64-ECMA (ECMA-182) was also
evaluated and while performing better than
CRC64-ISO still found collisions, where the same
checksum was generated by non-identical sequences.
(ii) nrdb: provided as part of the WU-BLAST package
(15), proved not to be robust enough to deal with
large-size data sets.
(iii) CD-HIT (16): clusters sequences eﬃciently using
short word ﬁlters but discards short sequences and
merges overlapping sequences of diﬀering length.
Figure 1. Data growth of EMBL-Bank patent class. The curve
indicates the number of entries in the EMBL-Bank patent class has
increased dramatically during the past decade.
Nucleic Acids Research, 2010,Vol.38, Database issue D53(iv) SHA checksums (http://www.itl.nist.gov/ﬁpspubs/
ﬁp180-1.htm): proved to be capable of distinguish-
ing the currently available sequences; however, they
are resource intensive.
(v) MD5 checksum: correctly distinguish the available
sequences and are viewed by the database providers
as a replacement for the current CRC checksums
provided in the data.
On the basis of this evaluation MD5 checksums were
chosen to identify identical sequences. Sequences with the
same checksum are considered identical, conversely
sequences with diﬀerent checksums are considered non-
identical. A level-1 cluster contains identical sequences
originating from diﬀerent patent documents, which may
belong to diﬀerent patent families, and thus may have
biological annotations from diﬀerent contexts (e.g. diﬀer-
ent organisms).
Level-1 cluster sequences were grouped into a level-2
cluster if they belonged to a same patent family; otherwise
they were grouped into diﬀerent level-2 clusters (Figure 2).
A patent family is the collection of all the equivalent
patents describing the same invention ﬁled with diﬀerent
patent oﬃces around the world. Please see Supplementary
Data Section 1 for more patent-related terminology.
Patent publication numbers associated with the sequences
were corrected and then patent family information and
international classiﬁcations (IPC classes) were extracted
from the Open Patent Services (OPS) (17). Level-1
cluster sequences without patent family information
were separated into individual level-2 clusters. For
example, level-1 cluster NRP_AX000635 contains 15
members (Supplementary Data Section 4.2). Using the
patent equivalent information (Supplementary Data
Section 4.3), USPTO proteins AAN97218 and BE25759
belong to one patent family (family number 26846334);
USPTO proteins AAO99687 and AAS33207 belong to
another patent family (family number 27576013); the
Korean protein DI578933 does not have family informa-
tion; and the other members belong to 10 diﬀerent patent
families. Therefore, this cluster (NRP_AX000635) was
split into 13 level-2 clusters (NRP00180079 through
NRP00180085, Supplementary Data Section 4.4).
For the 8300915 patent nucleotide entries in EMBL-
Bank release 99; 5167627 level-1 clusters (NRNL1) and
6714564 level-2 clusters (NRNL2) were obtained. For the
3307421 patent protein entries of 21 May 2009; 1371866
level-1 clusters (NRPL1) and 2281606 level-2 clusters
(NRPL2) were obtained (Table 1). A nucleotide or a
protein sequence appeared in 1.30 or 1.66 patent
families, respectively.
Annotations
The non-redundant patent sequence databases have added
value with respect to the existing patent sequence
repositories. Additional information that is legally impor-
tant to the intellectual-property world was provided.
Earliest publication dates are required to identify
relevant prior art. The earliest publication date was deter-
mined for each cluster by comparing the patent publica-
tion dates amongst all the cluster members. Correct
publication numbers are important to identify the legal
status of the patent and to link to the patent full-text
document.
Figure 2. Steps to create non-redundant patent sequence databases
at two levels. Squares of the same colour represent level-1 sequences,
100% identical over the whole length. Squares of the same colour and
pattern represent level-2 sequences, which are identical and belong to
the same invention (i.e. patent family).
Table 1. Summary of two-level non-redundant patent sequence databases (based on the EMBL Release 99 of March 2009)
NR databases Abbreviation Coverage No. of entries Redundancy
before
NR patent nucleotides level-1 NRNL1 EMBL-Bank patents (8300915 entries) 5167627 1.61
NR patent nucleotides level-2 NRNL2 EMBL-Bank patents (8300915 entries) 6714564 1.24
NR patent proteins level-1 NRPL1 EPO, JPO, KIPO and USPTO patent proteins
(3307421 entries)
1371866 2.41
NR patent proteins level-2 NRPL2 EPO, JPO, KIPO and USPTO patent proteins
(3307421 entries)
2281606 1.45
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records (both nucleotide and protein), which are
associated with individual patents, discovered errors in
77.8% of the numbers. The errors detected include the
publication number (e.g. WO0112792), the publication
date, the Kind Code (KC; an indication of the legal
status of the patent application and its progress through
the patent process) and the publication level (ﬁrst avail-
ability versus subsequent publication, of the patent in the
prior art). The types and percentage of errors detected are
summarized in Figure 3.
A level-2 cluster contains identical sequences originating
from the same invention (same patent family) and has
biological annotations from the same context. Therefore,
the original annotations among the members of the same
level-2 cluster are expected to be the same. However,
diﬀerences have been discovered in some cases. To
provide relevant biological information for level-2
clusters, the feature tables of the source entries have
been merged and qualiﬁers added to indicate the origin
of the annotation.
Result format
Identiﬁers were assigned to the clusters. A level-1 cluster
identiﬁer begins with ‘NRN_’ for a nucleotide cluster and
‘NRP_’ for a protein cluster, followed by the accession
number of a source entry selected according to the
priority order of EPO, USPTO, JPO and KIPO for
members from diﬀerent patent oﬃces and alpha-numeric
order for members from the same patent oﬃce, e.g.
NRN_CS587094 and NRP_AX000635. A level-2 cluster
identiﬁer begins with ‘NRN’ for a nucleotide cluster and
‘NRP’ for a protein cluster, followed by eight hexadecimal
digits, e.g. NRN001DEAFE and NRP00000018. The
level-2 cluster identiﬁers are maintained across database
releases and an identiﬁer history is provided which
includes information about deletions and insertions
within the cluster. This is stored in a tab-delimited table,
allowing users to track interesting clusters in diﬀerent
releases.
The sequence data are stored in FASTA sequence
format, while the annotation data are stored in an
EMBL-like format. The FASTA sequence format header
begins with the cluster identiﬁer, followed by a publication
number, chosen from the set of publication numbers
associated with the cluster, using the same rules, as
were used to choose the accession number used in the
identiﬁer at level-1, and its KC. Examples of FASTA
format sequences for the clusters can be found in
Supplementary Data Section 3. Annotation ﬁles for both
levels provide information about the earliest patent pub-
lication within the cluster (e.g. the earliest publication
date, the corresponding publication number and its
complete kind code in the ED line), data references of
cluster members (DR block) and sequence information
(e.g. the sequence length as well as the MD5 checksum
in the SQ line). Corrected publication numbers are
described in additional PN lines, followed by the type of
correction (CC line). Level-2 annotation also indicates
the master patent family number of the cluster (MF
line), the earliest active priority number within the
family (PR line) and the merged features and qualiﬁers
(FT lines). Examples of annotation records for the
clusters are shown in Supplementary Data Section 4.
DATA ACCESS
The FASTA format sequences and annotation ﬁles for the
clusters are downloadable from the EMBL-EBI non-
redundant patent data webpage (http://www.ebi.ac
.uk/patentdata/nr/). Sequence similarity and homology
searches [e.g. FASTA (18), NCBI BLAST (19) and
WU-BLAST (15)] against the non-redundant databases
are available through the web interface (http://www.ebi
.ac.uk/Tools/sss/) and SOAP and REST style Web
Services (20). The non-redundant patent sequence
data and the patent equivalents are available for text
searching through the EMBL-EBI’s SRS server
(http://srs.ebi.ac.uk/).
CONCLUSIONS
Sequence similarity and homology searches against non-
redundant sequence libraries are faster and more sensitive
than the equivalent search using redundant sequence
databases since fewer entries have to be scanned, more
reliable statistics are obtained due the database being
smaller and the relationships between signiﬁcant hits are
easier to interpret. These databases are the ﬁrst publicly
available collection of non-redundant patent sequence
databases, at both the sequence and patent-family levels.
Searches against level-1 clusters result in identical or
similar sequences from the patent literature (i.e. each
sequence may correspond to multiple inventions);
searches against level-2 clusters result in identical or
similar sequences from the same invention and in eﬀect
this is searching for related patents and is not a pure
sequence space search. In addition, the level-2 data
Figure 3. Publication number error types detected in the sequence data
set (both nucleotide and protein). ‘KC only’ represents the errors of
incorrect KC only; ‘KC completeness only’ represents the errors of
incomplete KC only; ‘KC+PN’ represents the errors of wrong PN
and wrong KC; ‘KC completeness+PN’ represents the errors of
incomplete KC and wrong PN; ‘PN only’ represents the errors of
wrong PN only; ‘Publication Level only’ represents errors of publica-
tion level only; and ‘Pending’ represents publication numbers which
currently cannot be resolved and are pending for corrections.
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explore the original patent applications for related
intellectual-property annotation. The corrected publica-
tion numbers enhance the data quality, enabling proper
cross-referencing to patent full-text documents. Similarly,
the earliest publication dates oﬀer direct tracking of the
patent-application history, enabling eﬀective prior art
searches. The collation of feature annotation from the
members of the family provides better cross-referencing
and improved biological context.
Addition of data from commercial eﬀorts (e.g.
GENESEQ
TM) would improve data coverage; however,
restrictions on the use of these data mean that the non-
redundant sets could not be made publicly available.
Sequences originating from other patent oﬃces, more spe-
ciﬁcally other International Searching Authorities (ISAs),
would improve the public domain coverage without
imposing usage restrictions. The EPO and EMBL-EBI
are collaborating in the development of computer
applications that normalize patent sequence formats
(WIPO ST.25 or future XML standards) and enable
interoperability between these data and existing sequence
analysis software. This application will enable us to
include data from patents submitted to other patent
oﬃces in the public sequence databases. The broad
coverage of the non-redundant sequence databases
described here, and the enhanced accessibility to the
sequence data through these databases, improves the
utility of the existing patent sequence data for the life
sciences and intellectual-property communities.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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